JAMA psychiatry

Changes in Mental Health Diagnoses Over Time in 12 to 25-Year-Olds Using Early Treatment Services for Anxiety, Mood, and Psychotic Disorders

Updated

Abstract

Of 685 participants with nonspecific symptoms, 36.9% transitioned to attenuated syndromes over a median follow-up of 14 months.

  • Transition from stage 1a to stage 1b is linked to lower social functioning and engagement in education or employment.
  • Higher rates of transition are associated with manic-like experiences, psychotic-like experiences, self-harm, and older age.
  • Among 1370 participants in stage 1b, 12.8% progressed to full-threshold disorders.
  • Factors influencing this transition include psychotic-like experiences, circadian disturbance, use of psychiatric medication, and childhood psychiatric disorders.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict of Interest Disclosures: Dr E. M. Scott is medical director, Young Adult Mental Health Unit, St Vincent’s Hospital Darlinghurst; discipline leader of Adult Mental Health, School of Medicine, University of Notre Dame; Research Affiliate, The University of Sydney; and Consultant Psychiatrist. She has received honoraria from Laboratoires Servier and Eli Lilly and Company for presenting educational seminars related to the clinical management of depressive disorders and has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. She was the national coordinator of an antidepressant trial sponsored by Laboratoires Servier. Dr J. Scott is a visiting professor at Diderot University, the Norwegian University of Science and Technology, Swinburne University of Technology, and The University of Sydney and a Science Without Borders fellow (Brazil). She has received grant funding from the UK Medical Research Council and from the UK Research for Patient Benefit program. Dr Hickie was an inaugural Commissioner on Australia’s National Mental Health Commission (2012-18). He is the co-director, Health and Policy at the Brain and Mind Centre (BMC), University of Sydney. The BMC operates an early-intervention youth service at Camperdown under contract to headspace, National Youth Mental Health Foundation Ltd. Dr Hickie has previously led community-based and pharmaceutical industry–supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He was a member of the Medical Advisory Panel for Medibank Private until October 2017, a board member of Psychosis Australia Trust, and a member of Veterans Mental Health Clinical Reference group. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PricewaterhouseCoopers ([PwC] Australia; 45% equity) to deliver the $30 million Australian Government-funded Project Synergy (2017-2020; a 3-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. No other conflicts were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free